USA flag logo/image

An Official Website of the United States Government

Expression of Angiogenic Growth Factors in Keratinocytes

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
61006
Program Year/Program:
2003 / SBIR
Agency Tracking Number:
GM065025
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Stratatech Corporation
505 S. Rosa Road, Suite 169 Madison, WI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2003
Title: Expression of Angiogenic Growth Factors in Keratinocytes
Agency: HHS
Contract: 2R44GM065025-02
Award Amount: $774,329.00
 

Abstract:

DESCRIPTION (provided by applicant): Recent advances in tissue engineering hold great promise for alleviating the current shortage of tissues and organs available for transplantation. However, engineered skin tissue produced with primary human keratinocytes is slow to vascularize following engraftment, resulting in tissue ischemia and a low frequency of graft take. These limitations may be overcome by genetically modifying the tissue such that it produces factors that are known to promote vascularization and angiogenesis. The ultimate goal of these studies is to develop cultured skin tissue that exhibits accelerated vascularization and improved wound healing following engraftment. During Phase I, it was demonstrated that human NIKS TM keratinocytes can be stably modified to express elevated levels of angiogenic factors from non-viral vectors. This Phase II SBIR proposal is designed to expand upon progress made during Phase I by determining whether cultured skin tissue that expresses elevated levels of angiogenic growth factors will exhibit accelerated vascularization in an animal model of wound healing. The expression profiles and growth characteristics of multiple independent stably-transfected keratinocyte clones will be characterized to identify clones that express different levels of the angiogenic factors. Skin tissue prepared from these NIKS TM cells will be grafted onto mice and monitored over time to quantify the effect of angiogenic factor expression on wound healing and vascularization. Successful completion of these studies will position this technology for further pre-clinical assessment and ultimate evaluation in human clinical trials.

Principal Investigator:

Allen R. Comer
6084412750
ACOMER@STRATATECHCORP.COM

Business Contact:

Robert Barnard
6084412756
RBARNARD@STRATATTECHORP.COM
Small Business Information at Submission:

STRATATECH CORPORATION
STRATATECH CORPORATION 505 S ROSA RD MADISON, WI 53719

EIN/Tax ID: 391977193
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No